Skip to main content
. 2021 Mar 31;13(7):1612. doi: 10.3390/cancers13071612

Figure 2.

Figure 2

KRAS mutation status was determined in plasma from (a) sporadic PDAC cases (b) hereditary or familial PDAC (H/FPC) cases via BEAMing and mutant KRAS was more frequently detected H/FPC cases compared to sporadic cases. BEAMing was performed using cfDNA isolated from 1 mL of plasma from 54 PDAC cases (31 familial cases and 23 sporadic cases). The frequency of mutant KRAS 70% in sporadic cases and 16% in familial cases, which was statistically significant (p ≤ 0.001).